The role of RAB GTPases in predicting prognosis and therapy response in pancreatic cancer.

RAB GTP酶在预测胰腺癌预后和治疗反应中的作用

阅读:17
作者:Wang Jiayi, Ma Jiayao, Lei Shiying, Zhai Yulei, Liao Yangjie, Hu Chongrong, Li Jingbo
BACKGROUND: The Rab family of small GTPases (RABs) regulates membrane trafficking and is implicated in tumor progression. Pancreatic cancer (PC), a highly aggressive malignancy, lacks effective therapeutic strategies. Using bioinformatics and experimental validation, we identified five RABs (RAB10, RAB11A, RAB39B, RAB28, and RAB11B) to construct a RAB prognostic model (RPM) for PC. METHODS: Datasets from TCGA and GEO were analyzed using Cox and LASSO regression to establish RPM. A prognostic nomogram integrating RPM with clinical features was developed. Microenvironment and drug sensitivity analysis were performed to predict the relationship between RPM score and therapy response. In vitro experiments (CCK8, MDA assays, lentiviral knockdown, qPCR, and western blot) were performed to validate RAB39B’s role in autophagy-dependent ferroptosis. RESULTS: RPM stratified patients into high- and low-risk groups, with high-risk patients showing poorer overall survival. The low-risk group exhibited enriched immune infiltration, elevated HLA expression, higher dysfunctional T-cell scores, and lower tumor mutation burden, suggesting an exhausted tumor immune microenvironment which could benefit from immunotherapy. The high-risk cohort exhibited markedly reduced responsiveness to axitinib, gefitinib, imatinib, methotrexate, nilotinib, and sunitinib, while demonstrating enhanced sensitivity to erlotinib, lapatinib, and sorafenib. Correlation analysis further identified RAB39B as a critical modulator of treatment response. In vitro experiments demonstrated that RAB39B knockdown reduced ferroptosis inducibility and suppressed LC3-II accumulation, implicating RAB39B’s role in autophagy-dependent ferroptosis. CONCLUSIONS: RPM serves as a robust prognostic tool for PC. RAB39B drives autophagy-dependent ferroptosis and influences drug sensitivity, offering therapeutic insights for PC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-025-03209-4.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。